Learn Why Price T Rowe Associates Inc Purchased Genmark Diagnostics, Inc Stake?

August 10, 2017 - By reb123z

 Learn Why Price T Rowe Associates Inc  Purchased Genmark Diagnostics, Inc Stake?

Investors sentiment decreased to 1.43 in 2016 Q4. Its down 0.20, from 1.63 in 2016Q3. It worsened, as 10 investors sold GenMark Diagnostics, Inc shares while 20 reduced holdings. 11 funds opened positions while 32 raised stakes. 46.49 million shares or 1.00% less from 46.96 million shares in 2016Q3 were reported.

Northpointe Ltd, Michigan-based fund reported 859,349 shares. Td Asset Management Inc accumulated 99,000 shares. Millennium Mngmt Lc invested 0.02% of its portfolio in GenMark Diagnostics, Inc (NASDAQ:GNMK). Alliancebernstein Limited Partnership holds 56,100 shares or 0% of its portfolio. California State Teachers Retirement reported 89,774 shares. Geode Cap Limited Liability Company has invested 0% in GenMark Diagnostics, Inc (NASDAQ:GNMK). Fmr Ltd Com owns 0.01% invested in GenMark Diagnostics, Inc (NASDAQ:GNMK) for 6.96 million shares. Next invested in 0% or 840 shares. Weiss Multi invested 0.04% of its portfolio in GenMark Diagnostics, Inc (NASDAQ:GNMK). Savings Bank Of Montreal Can holds 0% or 779 shares. Putnam Investments Llc stated it has 0.12% in GenMark Diagnostics, Inc (NASDAQ:GNMK). Tower Capital Lc (Trc) invested 0% in GenMark Diagnostics, Inc (NASDAQ:GNMK). D E Shaw Co holds 10,217 shares or 0% of its portfolio. Rhumbline Advisers invested in 45,716 shares. Alyeska Invest Gp L P accumulated 179,523 shares.

Since February 14, 2017, it had 0 buys, and 33 selling transactions for $1.08 million activity. Shares for $20,134 were sold by MASSARANY HANY on Tuesday, March 7. The insider Kayyem Jon Faiz sold $3,788. Mendel Scott had sold 2,135 shares worth $27,520. Stier Eric sold $23,099 worth of GenMark Diagnostics, Inc (NASDAQ:GNMK) on Friday, May 19. Gleeson Michael sold $80,217 worth of stock or 7,958 shares.

The New Price T Rowe Associates Inc Holding in Genmark Diagnostics, Inc

Price T Rowe Associates Inc reported SC 13G/A form with the SEC for Genmark Diagnostics, Inc. Access it here: 000008025517001352. As reported by Price T Rowe Associates Inc , the filler owns 10.5% or 5,634,378 shares of the Health Care–company.

Genmark Diagnostics, Inc stake is new for [reportingPerson]. Date of activity: July 31, 2017. This shows Price T Rowe Associates Inc ’s positive view for Genmark Diagnostics, Inc. For a institutional investor managing $689.00 billion in assets and having 2216+ experts this is interesting position.

Genmark Diagnostics, Inc Institutional Sentiment

Filings show 85 investors own Genmark Diagnostics, Inc. The ownership in Q3 2015 is high, at 91.82 % of the outstanding shares. This is increased by 6973157. 50197158 were owned by these investors. 8 funds opened new Genmark Diagnostics, Inc stakes, 39 increased positions. There were 8 that closed positions and 25 reduced them.

Rmb Capital Management Llc is an investor bullish on Genmark Diagnostics, Inc, owning 1078127 shares as of Q3 2015 for 0.56% of its portfolio. Eric Bannasch Cadian Capital Management Lp owns 2660195 shares or 0.75% of its portfolio. NY Ghost Tree Capital Llc have 1.86% of its portfolio for 525000 shares. Further, Camber Capital Management Llc reported stake worth 0.49% of its portfolio. The MI Northpointe Capital Llc owns 1216481 shares. Genmark Diagnostics, Inc is 1.25% of its portfolio.

Business Profile

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

SEC Form 13G.

Price T Rowe Associates Inc website.

About 528,951 shares traded or 22.78% up from the average. GenMark Diagnostics, Inc (NASDAQ:GNMK) has risen 116.11% since August 10, 2016 and is uptrending. It has outperformed by 99.41% the S&P500.

GenMark Diagnostics, Inc. is a molecular diagnostics company. The company has market cap of $554.87 million. The Firm is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It currently has negative earnings. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

GenMark Diagnostics, Inc (NASDAQ:GNMK) Ratings Coverage

Among 3 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Genmark Diagnostics has $1700 highest and $8 lowest target. $14’s average target is 37.93% above currents $10.15 stock price. Genmark Diagnostics had 10 analyst reports since October 14, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Monday, August 7 with “Buy”. The firm has “Buy” rating given on Tuesday, January 24 by Needham. On Monday, June 12 the stock rating was maintained by Needham with “Buy”. The stock of GenMark Diagnostics, Inc (NASDAQ:GNMK) has “Buy” rating given on Monday, June 12 by Canaccord Genuity. Needham maintained the shares of GNMK in report on Wednesday, August 2 with “Buy” rating. The firm has “Buy” rating by Needham given on Wednesday, October 28. The firm has “Buy” rating given on Wednesday, February 24 by Needham. The firm has “Outperform” rating by Cowen & Co given on Friday, September 16.

More notable recent GenMark Diagnostics, Inc (NASDAQ:GNMK) news were published by: Seekingalpha.com which released: “GenMark Q2 miss sinks shares, down 16%” on August 01, 2017, also Seekingalpha.com with their article: “GenMark Diagnostics’ (GNMK) CEO Hany Massarany on Q4 2016 Results – Earnings …” published on March 01, 2017, Seekingalpha.com published: “Closer To ‘Go Time’, GenMark Diagnostics’ Ability To Execute Is Still A Key …” on May 17, 2017. More interesting news about GenMark Diagnostics, Inc (NASDAQ:GNMK) were released by: Fool.com and their article: “Why GenMark Diagnostics, Inc. Is Soaring Today” published on September 16, 2016 as well as Businesswire.com‘s news article titled: “GenMark Diagnostics Commences Public Offering of Common Stock” with publication date: June 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.